This document provides a summary of a comprehensive oncology intelligence report for 2013. The report contains over 800 pages divided into 6 sections with infographics and tables. It covers aspects of cancer drug development including companies, clinical trials, targets, indications and molecules in development. The report is designed to provide up-to-date intelligence on competition, collaboration patterns, emerging targets and research trends to help with strategic decision making. Each section analyzes the data through infographics and profiles of over 400 cancer-focused companies to explore research trends, development strategies and changes in the oncology landscape over time.

1. 2013
Oncology Intelligence
A Comprehensive Report for Decision Making

2. WHY I NEED A INTELLIGENCE REPORT ?
Report - covers all aspects of Cancer Drug Development Intelligence.
To Explore who is developing what ?
Exact Competition withlike Drug on Launch.
Designed my colorful magazine, for your reading pleasure.
Top companies/developers read in flight between San Francisco to Boston.
Can be stratergies.
Collaboration patterns to fill technology gap.
INFOGRAPHICS BASED INTELLIGENCE REPORT.
Emerging drug targets in cancer research.
Year on year, which indications are advancing ?
Role of emerging markets in sales/research competition?
etc., etc. and so on.

3. REPORT CONTAINS Interactive 820+ pages, divided into 6 Sections, with Infographics and Tables
most
updated
information 2663
Indications
142 In Trials
Cancer preclinical
Pipeline
Companies
462 210+
Cancer Cancer
Clinical Targets
Companies
1042
600+ Molecules in
Late-
Complete Clinical
Preclinical
Trials
Molecules 2012
Cancer Drug
Updates
Oncology Intelligence
A Comprenehsive Report for Decision Making 2013

4. REPORT IS DIVIDED IN 6 SECTIONS,
WITH INFOGRAPHICS AND CANCER COMPANIES PROFILES

5. ALL INFOGRAPHICS PAGES 462 COMPANIES Total 6 Pages with 14 Figures and 1 Table
Worldwide Distribution of Oncology focused companies, with active clinical pipeline.
Helps in identifying the research incubating countries.
Division of Companies on the Basis of Market/Assets Valuation and
Ownership, along with their country wise distribution.
Helps in identifying cancer research trends among Small, Mid & Large companies
also as Public, Private & Subsidiaries, and nation wise preferences for the sector.
Division of Cancer Companies on the basis of employee numbers
and Year of Incorporation.
Exploring cancer research funding needs and emergence of Cancer Drug Discovery
Industry, going ahead.
Distribution of Cancer Companies within United States of America.
Helps in identifying the cancer research hubs and research supporting states.

6. Few Sample Pages of Section A

7. PAGES CONTAINS INFOGRAPHICS & TABLES 1042 MOLECULES & 210+ TARGETS Total 55 Pages with 26 Figures & 25 Tables
Worldwide Distribution of cancer targeting molecules in clinical development.
Helps in identifying the emerging trends between Small molecules Vs. Biologics.
Molecule Developing Strategies - Top 10 Companies Vs. Remaining 452 Companies.
Identify How Big Pharma drug strategies are changing and what others are pursuing.
Cancer Drug Targets – Established Vs. Emerging Targets.
210+ cancer drug targets with complete details and drugs under development for each target.
Thus, helps in clearly identifying emerging targets.
Protein Kinases Inhibitors Development Strategies – Top 10 Vs. Others.
Established Protein Kinases Vs emerging protein kinases- development profiles.
Learn which companies are focusing more on PK and for which cancer indications.
Cancer Drugs in Development – mAbs , Vaccines, mAbs-drug conjugates
Gene Therapies & description of various others molecules.

8. Few Sample Pages of Section B
Page 2 & 3, shown above contains cuttings of various pages. For more details, kindly refer Table of Contents.

9. PAGES CONTAINS INFOGRAPHICS & TABLES 2663 DRUG INDICATIONS in 19 CANCER TYPES Total 81 Pages with 53 Figures & 91 Tables
Division of total drug Indications among top 19 cancer subtypes (like Lung, Breast, Melanoma, etc.)
Helps in identifying the emerging vs. current Cancer Indications.
Phase wise & Region wise, Distribution of Drug Indications.
Exploring ‘who’ is developing ‘what’?
Cancer Indications Development Strategies - Top 10 companies Vs. others.
Identifying the emerging cancer subtypes of interest among Big Pharma and their choice
towards development of small/biologics.
Complete Clinical Drug Development Profiles of 19 Cancer Subtypes.
Identifying the emerging Vs. underserved cancer subtype.
First Report which equally focuses underserved cancer subtypes.
Orphan Drug Status molecules and their cancer indications (USFDA & EMEA).
Oncology Clinical Pipeline –Major Advances/Failures & New Entrants - 2012.

10. Few Sample Pages of Section C
For more details, kindly refer Table of Contents.

11. PAGES CONTAINS TABLES ONLY Total 16 Pages with 9 Tables
Corporate Actions - 2012 Complete coverage of oncology focused events (1000+ events).
US FDA Oncology Drug Approvals - 2012
Mergers & Acquisitions -2012
Partnering & Collaborations - 2012
Oncology molecule – Assets Acquisition / Assets Termination - 2012
Company / Academic Partnerships - 2012
Venture Capital Financing - 2012
Key Management Appointments - 2012

12. Few Sample Pages of Section D
Pages 1,2 & 3, shown above contains cuttings of various pages. For more details, kindly refer Table of Contents.

13. PAGES CONTAINS 462 COMPANIES PROFILES Total 526 Pages
Focused 462 individual cancer clinical companies profiles – Mini Reports.
Companies having active clinical trials, with development & marketing rights of molecules in cancer treatment
are only included. No company with dead assets (trials-status unknown/last updated prior 2010) are included.
Profile contains Company’s key management, key oncology assets (both clinical & preclinical),
key collaborators, Investors, Molecules profile, targets & development strategies etc.
Only Oncology focused events are documented, to avoid any ambiguous data.
Profiles are written as mini-report for an individual company.
All Inferences are derived in this report in earlier sections are based on these
mini reports of companies’ , thus the report validates its data.
No Information is Duplicated.
The strongest point of Report, beside been precise is, no information is
duplicated anywhere, that helps to avoid confusions/errors.

14. Oncology focused :- Key
Highlights of Company, Key
technology, Collaborations, partn
ers, Approved pipeline, etc.
Cancer Targeted Molecules in
Clinical Development:-
Molecule name(s), Target, Clinical
Phase, all possible Indications of
development of the molecule,
Last Updated on Clinical Trials
with Trial Status as on Dec 2012 &
Drug type (Small/Biologic/NBCM).
Key Highlights of Drugs in
Development :- Drug’s Target
Description, Mechanism of
Action, Orphan Status, Preclinical
Management Profile: Contact Address, Founded Pipeline etc.
Year, Ownership, Key Management People, Stock Ticker and Market
Capitalization
Company Profile Pages – Merck Serono

15. PAGES CONTAINS 142 COMPANIES PROFILES Total 95 Pages
Focused profiles of individual cancer companies, with active preclinical pipeline.
Companies with molecules in late preclinical development for cancer treatment.
Exclusive focus on Partnering and Emerging Proprietary Technology.
Description of First in class with molecules available for partnering.
Covers 300+ molecules in preclinical development.
Reports covers 600+ disclosed Preclinical Molecules in development by both clinical
and preclinical companies.
Only Late Preclinical Pipeline companies are included.
No Exclusive Cancer Discovery Phase Companies are covered to avoid ambiguity.
Cancer Companies Profiles are in form of Mini-Reports.
Covers Management profile, Key Investors, Key Technology Partners, pipeline
description etc.

16. Company Details
Key Management Profile.
Key Technology Platform.
Key Technology Partners,
Key Investors & other Company
and Cancer Drug Highlights.
Preclinical Pipeline Details with
Targets and Indications Detail.
Few Sample Pages of Section F For more details, kindly refer Table of Contents.

17. Highly Innovative Report – contains all aspects of Oncology Drug Intelligence.
First Infographics Report – Figures can also be used in Presentations.
Largest Coverage –First Report which covers 620+ companies with 1600+ molecules
details and complete pipeline analysis.
First Scientific Report which extensively focuses on technologies and drug targets.
Precise Information – All Efforts are done to reproduce Accurate Information.
Value for Money - The report is an excellent value for money, without
2799/- USD compromising the quality. This is all possible by
Prior 28th Feb 2013 reducing our marketing expenses (comprises nearly
e-copy only. 60-70% of report cost) and utilizing more resources in
Including all taxes. developing quality content.
Price reflects approx. 4$ for Individual Company Report !!!!!!

18. Opinion on Oncology Intelligence 2013:
During Jan 2013, about 316 free preview copies of Oncology Intelligence 2013 were
distributed to Industry leaders working in area of oncology drug development through
LinkedIn invitation call and nearly all of them replied very positive on the report.
We are sharing few industry leaders comment on their consent.
It is an excellent report that has a wide variety of oncology information all in
one place.
Dr. Oleh Denysyk
This report contains enough data to make strategic decisions especially for
new entrants.
Dr. Mitsuyoshi Nishizaki
It is difficult to believe this quality of work from start up company.
Dr. Gilbert Parker
Classic work esp. Section B with facts on oncology targets and drug alliances.
Dr. Shohko Iwami

19. Intelligent BioSolutions
OmicsX design and develop highly innovative comprehensive intelligence reports to
provide complete 3600 view to its readers. Starting 2013, every second month we are
lined up with knowledge centered reports in life science. Each report reflects Team
OmicsX in-depth knowledge and innovative out of the box thinking. We works for
several month to craft a single original content interactive report at very competitive
price, with only one aim in mind to provide quality and precise information to our
clients which will help in decision support. Reports contains Insights and analysis at the
company, country and disease level, which includes individual company’s profiles and
market data, valuations, clinical & market trends, product pipelines and forecasts.
For Details and Enquiries on our Customized Services, Contact
Virendra Singhvi
Manager – Business Development
virendra.singhvi@omicsx.com
+1-646-523-4433
+44-203-608-3536
+91-562-2281122